{"id":403142,"date":"2010-03-08T10:06:46","date_gmt":"2010-03-08T15:06:46","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=67208"},"modified":"2010-03-08T10:06:46","modified_gmt":"2010-03-08T15:06:46","slug":"isis-nabs-6m-bristol-payment","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/403142","title":{"rendered":"Isis Nabs $6M Bristol Payment"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Drugs\/\">Drugs<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/cholesterol\/\">Cholesterol<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Isis Pharmaceuticals (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=ISIS\">ISIS<\/a>), the Carlsbad, CA-based biotech company, <a href=\"http:\/\/ir.isispharm.com\/phoenix.zhtml?c=222170&amp;p=irol-newsArticle&amp;ID=1399834&amp;highlight=\">said today<\/a> it has earned a $6 million payment from Bristol-Myers Squibb for getting clearance from regulators to begin clinical trials of a new cholesterol-lowering drug. Isis and Bristol are collaborating on BMS-PCSK9Rx, as a targeted antisense therapy which seeks to lower cholesterol by hitting the target PCSK9.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/03\/08\/isis-nabs-6m-bristol-payment\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Isis%20Nabs%20$6M%20Bristol%20Payment%20http:\/\/xconomy.com\/?p=67208\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/03\/08\/isis-nabs-6m-bristol-payment\/&#038;t=Isis%20Nabs%20$6M%20Bristol%20Payment\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/03\/08\/isis-nabs-6m-bristol-payment\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Isis+Nabs+%246M+Bristol+Payment&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F03%2F08%2Fisis-nabs-6m-bristol-payment%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=4b7e5baf3fe9a1544d5c853aaed755b3&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=4b7e5baf3fe9a1544d5c853aaed755b3&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/3DCowd9g9exudbG6QnOasZz14KY\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/3DCowd9g9exudbG6QnOasZz14KY\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/3DCowd9g9exudbG6QnOasZz14KY\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/3DCowd9g9exudbG6QnOasZz14KY\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/zsHKd7Di2mM\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Drugs, Cholesterol Luke Timmerman wrote: Isis Pharmaceuticals (NASDAQ: ISIS), the Carlsbad, CA-based biotech company, said today it has earned a $6 million payment from Bristol-Myers Squibb for getting clearance from regulators to begin clinical trials of a new cholesterol-lowering drug. Isis and Bristol are collaborating on BMS-PCSK9Rx, as a targeted antisense therapy which seeks [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-403142","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/403142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=403142"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/403142\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=403142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=403142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=403142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}